Search global stocks & ETFs...Ctrl K
Learn Mode
Guardant Health IncGH
$125.61
-$7.45 (-5.599%)
$124.01
-$1.60 (-1.271%)
GH
Stock Profile
07-28
Recommended Metric
Score Card
Explore Scores Tab
2.80
Average
Valuation Model
Key Score
4.00
Good
Management
3.00
Average
Growth
4.00
Good
Profitability
1.00
Very Bad
Fin. Health
2.00
Bad
Dividends
--
--
Analyst
3.00
Average
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$125.61
Baseline
High
$199.50
▲
58.82%
Avg
$133.79
▲
6.51%
Low
$64.07
▼
-48.99%
Analyst Ratings based on 32 Analysts
Strong Buy
1444%
Buy
1547%
Hold
309%
Sell
000%
Strong Sell
000%
Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 2,490 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.Read More
Stock News
View All Updates
News80%Bullish
Guardant Health, Inc. (GH) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow
5hSeekingAlpha
Goldman Sachs Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $165
16hBenzinga
Wall Street Lunch: NVIDIA CEO Huang's $1T Marvell Call Triggers $40B Rally, Crushing Puts
3dSeekingAlpha
CrowdStrike To Gain 7%? Here Are 10 Top Analyst Forecasts For Tuesday
3dBenzinga
This Evercore ISI Group Analyst Turns Bullish; Here Are Top 2 Upgrades For Tuesday
3dBenzinga
Wolfe Research Assumes Guardant Health at Outperform, Announces Price Target of $150
3dBenzinga
Evercore ISI Group Upgrades Guardant Health to Outperform, Raises Price Target to $160
3dBenzinga
Testing & Diagnostics Services Stocks Q1 Earnings: Guardant Health (NASDAQ:GH) Firing on All Cylinders
1wYahoo
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
1wYahoo
Guardant Health To Present 38 Abstracts, As Well As One Oral Presentation In Partnership With Pfizer, Showcasing Advances In Methylation-Based Tumor Classification And Liquid Biopsy Technology At ASCO Annual Meeting 2026
1wBenzinga
Baron Health Care Fund Q1 2026 Portfolio Activity
1wSeekingAlpha
Guardant Health Just Broke Out On Bullish News For Its Colon Cancer-Detecting Blood Test
1wYahoo
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Amid S&P 500, Nasdaq Rally, Middle East Peace Optimism
1wYahoo
BTIG Maintains Buy on Guardant Health, Raises Price Target to $160
1wBenzinga
American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
1wYahoo
Guardant Health Says Its FDA-Approved Shield Blood Test Is Now Included In Updated American Cancer Society Colorectal Cancer Screening Guidelines
1wBenzinga
3 Growth Stocks We’re Skeptical Of
1wYahoo
BTIG Maintains Buy on Guardant Health, Raises Price Target to $155
1wBenzinga
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
1wYahoo
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
1wYahoo
D-Wave, Dell, And IonQ Are Among Top 10 Large-Cap Gainers Last Week (May 18-May 22): Are the Others in Your Portfolio?
1wBenzinga
A Look At Guardant Health’s Valuation After Its Recent Share Price Surge
1wYahoo
Guardant Health (GH) Is Up 25.3% After FDA Clears First Genomic‑Epigenomic Liquid Biopsy Panel – Has The Bull Case Changed?
1wYahoo
3 of Wall Street’s Favorite Stocks Walking a Fine Line
2wYahoo
Guardant wins FDA approval for updated liquid biopsy
2wYahoo
Guardant Health Leaps On A Major Win In Cancer Detection; Will Shares Break Out?
2wYahoo
Guardant Health Secures FDA Approval For Expanded Liquid Biopsy Test
2wBenzinga
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
2wYahoo
Guardant Health Announces FDA Approval Of The Company's Liquid CDx To Advance Blood-Based Comprehensive Genomic Testing
2wBenzinga
Why Guardant Health (GH) Stock Is Down Today
2wYahoo
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2wYahoo
The Top 5 Analyst Questions From Guardant Health’s Q1 Earnings Call
2wYahoo
Guardant Health (GH) Q1 Revenue Jumps 48% to $301.7M on Strong Screening Growth
2wYahoo
Guardant Health: Reveal And Shield Driving The Next Growth Phase
3wSeekingAlpha
Guardant Health : Corporate Responsibility Report 2026
3wFinnhub
GH Q1 Deep Dive: Shield Volume Acceleration and Oncology Portfolio Expansion Fuel Growth
3wYahoo
Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
3wSeekingAlpha
Transcript : Guardant Health, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 10
3wFinnhub
Evercore ISI Keeps an “In Line” Rating on Guardant Health, Inc. (GH)
3wYahoo
Guardant Health : Q1 2026 Earnings Call
4wFinnhub
JP Morgan Maintains Overweight on Guardant Health, Raises Price Target to $135
4wBenzinga
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine
4wSeekingAlpha
Barclays Maintains Overweight on Guardant Health, Raises Price Target to $120
4wBenzinga
Evercore ISI Group Maintains In-Line on Guardant Health, Raises Price Target to $95
4wBenzinga
Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript
4wSeekingAlpha
Transcript : Guardant Health, Inc., Q1 2026 Earnings Call, May 07, 2026
4wFinnhub
Guardant Health (NASDAQ:GH) Smashes Q1 Estimates, Raises Full-Year Guidance on Soaring Screening Revenue
4wChartMill
Guardant Health, Inc. 2026 Q1 - Results - Earnings Call Presentation
4wSeekingAlpha
Guardant Health: Q1 Earnings Snapshot
4wFinnhub
Guardant Health Raises FY2026 Sales Guidance from $1.250B-$1.280B to $1.300B-$1.320B vs $1.271B Est
4wBenzinga